Drug intelligence / Profile preview

Wenrun Xinjin Peiben Granules

Development stage: Preclinical
Lead developer: China-Japan Friendship Hospital
Administration: Oral

Overview

Wenrun Xinjin Peiben Granules is a Traditional Chinese Medicine (TCM) formulation developed by the China-Japan Friendship Hospital for the treatment of chronic eczema. The formulation is designed to address TCM syndromes such as blood deficiency and wind-dryness, which are common in persistent skin conditions. Its name, "Wenrun Xinjin Peiben," refers to the therapeutic actions of warming and moistening (Wenrun) and strengthening the foundation (Peiben). The drug is administered orally as granules and has been evaluated in clinical trials in China to compare its efficacy against conventional pharmacological treatments for adult patients with chronic eczema.

Other names: Wenrun Xinjin Peiben Keli

Beyond the preview

Go deeper on Wenrun Xinjin Peiben Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wenrun Xinjin Peiben Granules.

Explore the full profile